Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.

Alimentary pharmacology & therapeutics - 1 Jul 2001

Di Marco V, Vaccaro A, Ferraro D, Alaimo G, Rodolico V, Parisi P, Peralta S, Di Stefano R, Almasio P L, Craxì A

Abstract excerpt

BACKGROUND: Therapy of chronic hepatitis C non- responders to interferon monotherapy with standard doses of interferon plus ribavirin is usually ineffective. AIM: To evaluate the efficacy and tolerability of high-dose prolonged combination retreatment in non- responder patients. METHODS: Patients were retreated for 6 months with 6 MU alphaIFN on alternate days and 1000 or 1200 mg/day ribavirin. HCV-RNA negative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Drug Therapy, Combination

Share to Fibrosis

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Ribavirin

Source

Identifiers

PMID: 11421869
DOI: 10.1046/j.1365-2036.2001.01005.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.PMID 11421869Read ↗

Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.Semantic proximity Read ↗

Therapy of chronic hepatitis C: a critical review.Semantic proximity Read ↗

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.Semantic proximity Read ↗

Current therapy for hepatitis C.Semantic proximity Read ↗

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.Semantic proximity Read ↗

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.Semantic proximity Read ↗

Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.Semantic proximity Read ↗

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.Semantic proximity Read ↗

Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.Semantic proximity Read ↗

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.Semantic proximity Read ↗

Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.Semantic proximity Read ↗

Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.